Stevanato Group announced it has secured €200 million in financing through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM. This funding is designated to support the company’s ongoing capital expenditure projects in Cisterna di Latina, Italy, and Fishers, Indiana, U.S.
CDP committed €50 million specifically to enhance the production of pre-filled syringes and establish future capacity for ready-to-use (RTU) cartridges at the Latina plant. BNL BNP Paribas provided €100 million, and Banco BPM contributed €50 million, both aimed at scaling pre-filled syringe production in North America and Italy, and completing device manufacturing in Fishers.
This financing is a crucial element of Stevanato Group's financial strategy, enabling the company to capitalize on robust customer demand and support its long-term growth objectives. The funds will bolster capacity expansion efforts and the scaling of commercial production for growing biologics programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.